Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01923181 · ClinicalTrials.gov registry record · Phase 2

Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

A Phase 2 study of Diabetes Mellitus, Type 2 and Diabetes, sponsored by Novo Nordisk A/S.

Completed
Registry status
Phase 2
Development phase
632
Enrollment target
20
Study locations

NCT01923181 is a Phase 2 study of Diabetes Mellitus, Type 2 and Diabetes that has completed, run by Novo Nordisk A/S. The registered enrollment target is 632 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01923181, a Phase 2 study of Diabetes Mellitus, Type 2 and Diabetes, has completed, sponsored by Novo Nordisk A/S.

COMPLETED
Registry status
Phase 2
Development phase
632 participants
Enrollment target
20
Study locations

Study Summary

This trial is conducted globally. The aim of the trial is to examine the dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes.

Conditions Studied

Diabetes Mellitus, Type 2 Diabetes

Interventions

  • DRUG semaglutide
  • DRUG oral placebo

Study Locations (20)

California

  • Novo Nordisk Investigational Site - Chula Vista
  • Novo Nordisk Investigational Site - Long Beach
  • Novo Nordisk Investigational Site - Poway
  • Novo Nordisk Investigational Site - Santa Ana
  • Novo Nordisk Investigational Site - Spring Valley
  • Novo Nordisk Investigational Site - Walnut Creek

Florida

  • Novo Nordisk Investigational Site - Jacksonville
  • Novo Nordisk Investigational Site - Miami
  • Novo Nordisk Investigational Site - Plantation
  • Novo Nordisk Investigational Site - South Miami

Colorado

  • Novo Nordisk Investigational Site - Colorado Springs
  • Novo Nordisk Investigational Site - Denver

Georgia

  • Novo Nordisk Investigational Site - Athens
  • Novo Nordisk Investigational Site - Conyers

Illinois

  • Novo Nordisk Investigational Site - Addison
  • Novo Nordisk Investigational Site - Chicago

Arizona

  • Novo Nordisk Investigational Site - Tucson

Kansas

  • Novo Nordisk Investigational Site - Wichita

Maryland

  • Novo Nordisk Investigational Site - Rockville

Trial Details

FieldValue
Enrollment Target 632 participants
Start Date 2013-12-02
Est. Completion 2014-12-11
Phase Phase 2

Sponsor

Novo Nordisk A/S

431 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01923181

The ClinicalTrials.gov registry entry for NCT01923181 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 632 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (86% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which semaglutide is the first listed.

NCT01923181 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Colorado.

Frequently Asked Questions

What is clinical trial NCT01923181 about?

NCT01923181 is a clinical study titled "Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes". This trial is conducted globally. The aim of the trial is to examine the dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes.

What is the current status of trial NCT01923181?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 632 participants. The study started on 2013-12-02. Estimated completion is 2014-12-11.

What conditions does trial NCT01923181 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes.

What interventions are being tested in trial NCT01923181?

The interventions under investigation include: semaglutide (DRUG), oral placebo (DRUG).

Who is sponsoring clinical trial NCT01923181?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01923181 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetes Mellitus, Type 2

All registered trials for this condition

Diabetes

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.